Pharmacogenetics of immunosuppressants: Progress, pitfalls and promises

D. Cattaneo, S. Baldelli, N. Perico

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Most of the immunosuppressants used in organ transplantation are characterized by a narrow therapeutic index, whereby underdosing is associated with increased risk of rejection episodes and overdosing may exacerbate drug-related toxicity. Pharmacogenetics - complementary to pharmacokinetics - holds the potential to allow individualized dosing of immunosuppressive agents to optimize their therapeutic actions while minimizing adverse effects. Most of the studies have focused on polymorphisms of genes involved in drug metabolism and distribution, but as of now, only thiopurine-S-methyltransferase and cytochrome P 450 3A5 genotypes appear to have sufficiently large influence to have potentialities in guiding drug dosing. This may reflect the fact that available information from other polymorphisms derives almost exclusively from retrospective observations or from studies with important methodological biases. Active investigations aimed at identifying allelic variants of gene encoding for the pharmacologic targets are now ongoing. Recent studies have demonstrated that also donor genotype may play a significant role in immunosuppressive drug pharmacokinetics and pharmacodynamics. As one of the main future tasks, it is mandatory to develop mathematical models able to incorporate multiple gene polymorphisms with pharmacokinetic data and other critical information, providing algorithms able to individualize the best immunosuppressive therapy for each patient before transplantation.

Original languageEnglish
Pages (from-to)1374-1383
Number of pages10
JournalAmerican Journal of Transplantation
Volume8
Issue number7
DOIs
Publication statusPublished - Jul 2008

Fingerprint

Pharmacogenetics
Immunosuppressive Agents
Pharmacokinetics
thiopurine methyltransferase
Genotype
Pharmaceutical Preparations
Genes
Organ Transplantation
Drug-Related Side Effects and Adverse Reactions
Cytochrome P-450 Enzyme System
Theoretical Models
Therapeutics
Transplantation
Tissue Donors

Keywords

  • Organ transplantation
  • Pharmacodynamics of immunosuppressants
  • Pharmacogenetics
  • Pharmacokinetics of immunosuppressive agents

ASJC Scopus subject areas

  • Immunology

Cite this

Pharmacogenetics of immunosuppressants : Progress, pitfalls and promises. / Cattaneo, D.; Baldelli, S.; Perico, N.

In: American Journal of Transplantation, Vol. 8, No. 7, 07.2008, p. 1374-1383.

Research output: Contribution to journalArticle

@article{5db2c5dd3b6a45b6bc45fa59630e90b6,
title = "Pharmacogenetics of immunosuppressants: Progress, pitfalls and promises",
abstract = "Most of the immunosuppressants used in organ transplantation are characterized by a narrow therapeutic index, whereby underdosing is associated with increased risk of rejection episodes and overdosing may exacerbate drug-related toxicity. Pharmacogenetics - complementary to pharmacokinetics - holds the potential to allow individualized dosing of immunosuppressive agents to optimize their therapeutic actions while minimizing adverse effects. Most of the studies have focused on polymorphisms of genes involved in drug metabolism and distribution, but as of now, only thiopurine-S-methyltransferase and cytochrome P 450 3A5 genotypes appear to have sufficiently large influence to have potentialities in guiding drug dosing. This may reflect the fact that available information from other polymorphisms derives almost exclusively from retrospective observations or from studies with important methodological biases. Active investigations aimed at identifying allelic variants of gene encoding for the pharmacologic targets are now ongoing. Recent studies have demonstrated that also donor genotype may play a significant role in immunosuppressive drug pharmacokinetics and pharmacodynamics. As one of the main future tasks, it is mandatory to develop mathematical models able to incorporate multiple gene polymorphisms with pharmacokinetic data and other critical information, providing algorithms able to individualize the best immunosuppressive therapy for each patient before transplantation.",
keywords = "Organ transplantation, Pharmacodynamics of immunosuppressants, Pharmacogenetics, Pharmacokinetics of immunosuppressive agents",
author = "D. Cattaneo and S. Baldelli and N. Perico",
year = "2008",
month = "7",
doi = "10.1111/j.1600-6143.2008.02263.x",
language = "English",
volume = "8",
pages = "1374--1383",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Pharmacogenetics of immunosuppressants

T2 - Progress, pitfalls and promises

AU - Cattaneo, D.

AU - Baldelli, S.

AU - Perico, N.

PY - 2008/7

Y1 - 2008/7

N2 - Most of the immunosuppressants used in organ transplantation are characterized by a narrow therapeutic index, whereby underdosing is associated with increased risk of rejection episodes and overdosing may exacerbate drug-related toxicity. Pharmacogenetics - complementary to pharmacokinetics - holds the potential to allow individualized dosing of immunosuppressive agents to optimize their therapeutic actions while minimizing adverse effects. Most of the studies have focused on polymorphisms of genes involved in drug metabolism and distribution, but as of now, only thiopurine-S-methyltransferase and cytochrome P 450 3A5 genotypes appear to have sufficiently large influence to have potentialities in guiding drug dosing. This may reflect the fact that available information from other polymorphisms derives almost exclusively from retrospective observations or from studies with important methodological biases. Active investigations aimed at identifying allelic variants of gene encoding for the pharmacologic targets are now ongoing. Recent studies have demonstrated that also donor genotype may play a significant role in immunosuppressive drug pharmacokinetics and pharmacodynamics. As one of the main future tasks, it is mandatory to develop mathematical models able to incorporate multiple gene polymorphisms with pharmacokinetic data and other critical information, providing algorithms able to individualize the best immunosuppressive therapy for each patient before transplantation.

AB - Most of the immunosuppressants used in organ transplantation are characterized by a narrow therapeutic index, whereby underdosing is associated with increased risk of rejection episodes and overdosing may exacerbate drug-related toxicity. Pharmacogenetics - complementary to pharmacokinetics - holds the potential to allow individualized dosing of immunosuppressive agents to optimize their therapeutic actions while minimizing adverse effects. Most of the studies have focused on polymorphisms of genes involved in drug metabolism and distribution, but as of now, only thiopurine-S-methyltransferase and cytochrome P 450 3A5 genotypes appear to have sufficiently large influence to have potentialities in guiding drug dosing. This may reflect the fact that available information from other polymorphisms derives almost exclusively from retrospective observations or from studies with important methodological biases. Active investigations aimed at identifying allelic variants of gene encoding for the pharmacologic targets are now ongoing. Recent studies have demonstrated that also donor genotype may play a significant role in immunosuppressive drug pharmacokinetics and pharmacodynamics. As one of the main future tasks, it is mandatory to develop mathematical models able to incorporate multiple gene polymorphisms with pharmacokinetic data and other critical information, providing algorithms able to individualize the best immunosuppressive therapy for each patient before transplantation.

KW - Organ transplantation

KW - Pharmacodynamics of immunosuppressants

KW - Pharmacogenetics

KW - Pharmacokinetics of immunosuppressive agents

UR - http://www.scopus.com/inward/record.url?scp=47249151375&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47249151375&partnerID=8YFLogxK

U2 - 10.1111/j.1600-6143.2008.02263.x

DO - 10.1111/j.1600-6143.2008.02263.x

M3 - Article

C2 - 18510642

AN - SCOPUS:47249151375

VL - 8

SP - 1374

EP - 1383

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 7

ER -